Cooperation Invitation | Frost & Sullivan '2026 Global Immune Cell Therapy Industry Development Blue Book'

In recent years, with the continuous advancements in cell engineering, gene editing, and immune modulation technologies, the global immune cell therapy industry is entering a new stage of development. Immune cell therapy, represented by CAR-T, has been commercialized in the field of malignant tumors of the blood system and is gradually expanding to areas such as solid tumors and autoimmune diseases. Meanwhile, technical approaches such as TCR-T, TIL, NK, and CAR-NK are being further promoted. Emerging technologies such as allogeneic cell therapy and in vivo cell engineering also provide new avenues for exploration regarding the production model, clinical application, and future industrialization of cell therapy.

Beyond technological innovation, the competitive dimensions of the immune cell therapy industry are also expanding. From target discovery, cell engineering modification, and clinical development, to process optimization, large-scale production, quality control, and commercial delivery, the collaborative capabilities across the entire supply chain are increasingly becoming a key factor driving the industry’s growth. Additionally, companies are accelerating the integration of technology platforms and product pipeline development through strategic partnerships, technology licensing, mergers and acquisitions, and joint development initiatives, resulting in the ongoing evolution of the global immune cell therapy industry ecosystem.

Based on its ongoing research in the global healthcare industry, Frost & Sullivan (hereafter referred to as "Frost & Sullivan") has officially launched the research and drafting of the '2026 Global Immune Cell Therapy Industry Development Blue Book'.

This blue book will focus on the global and Chinese markets, systematically reviewing the technical development, clinical application, market size, competitive landscape, and industry ecosystem of immune cell therapy. It will also analyze industry trends, key challenges, and future opportunities by combining representative products, companies, and industry cooperation cases, providing professional industry research references for companies engaged in immune cell therapy, research institutions, medical institutions, industry investors, and related professionals.

01｜Technical Path Evolution and Supply Chain Analysis

This book will systematically outline the definition, classification, mechanism of action, and main technical pathways of immune cell therapy, with a focus on analyzing the development characteristics of CAR-T, TCR-T, TIL, NK, CAR-NK, DC, macrophage, and other immune cell therapy technologies. It will compare the cell source, preparation process, quality control, and clinical application features of different technical models, including autologous, allogeneic, and in vivo cell engineering, and further analyze the development of supply chain segments such as cell resource storage.

02｜Global and Chinese Market Size and Competitive Landscape

This book will review the current status and size changes in the global and Chinese immune cell therapy markets, analyzing the distribution of approved products, commercialization progress, and market competition structure across dimensions such as cell type, technical pathway, target, indication, and region. It will also, in conjunction with the research stages and technical pathways of global and Chinese under-development products, examine the distribution of the industry’s research pipeline, technical iteration directions, and future market growth potential.

03｜Key Disease Areas and Clinical Application Progress

Focusing on three key application areas: malignant tumors of the blood system, solid tumors, and autoimmune diseases, this book will outline the patient population, existing treatment methods, and unmet clinical needs for these major diseases. Combining representative products and clinical research progress, it will focus on analyzing the clinical application progress, technical breakthroughs, and future development potential of immune cell therapy in malignant tumors of the blood system, solid tumors, and autoimmune diseases.

04｜Industry Trends and Key Challenges

Centering on technical directions such as novel target development, multi-target design, allogeneic product-based cell therapy, in vivo cell engineering, automation, and closed production, this book will analyze the future technical evolution trends in the industry. It will also address key challenges such as clinical efficacy, safety, production process, batch consistency, large-scale manufacturing, payment systems, and commercial delivery, and explore the core drivers that facilitate the industry’s transition from clinical breakthroughs to industrialization.

05｜Investment, Industry Cooperation, and Capital Market Dynamics

This book will outline representative financing, technology licensing, merger and acquisition, and strategic partnership cases in the global and Chinese immune cell therapy fields, analyzing the technology platforms, product rights, and cooperation models involved in these transactions. It will also, in conjunction with the research progress, product approval, and commercialization layout of representative listed companies, analyze the flow of industrial capital, corporate strategic positioning, and industry integration trends.

06｜Representative Companies and Industrial Practices

This book will select representative global and Chinese immune cell therapy companies, cell resource storage companies, and industrial service platforms, and introduce their development history, core technology platforms, key product pipelines, clinical research progress, and production capabilities. Through company cases, it will present the industrialization practices of different technical pathways and the differentiated development paths of companies in process development, quality management, clinical translation, and commercialization layout.